Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success
Autore:
Winblad, B; Brodaty, H; Gauthier, S; Morris, JC; Orgogozo, JM; Rockwood, K; Schneider, L; Takeda, M; Tariot, P; Wilkinson, D;
Indirizzi:
Huddinge Univ Hosp, Karolinska Inst, Alzheimer Res Ctr, NEUROTEC, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 TEC, S-14186 Huddinge, Sweden Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia Univ New S Wales Sydney NSW Australia h Psychiat, Sydney, NSW, Australia McGill Ctr Studies Aging, Montreal, PQ, Canada McGill Ctr Studies Aging Montreal PQ Canada Aging, Montreal, PQ, Canada Washington Univ, Sch Med, St Louis, MO 63130 USA Washington Univ St LouisMO USA 63130 iv, Sch Med, St Louis, MO 63130 USA Univ Hosp Pellegrin, Bordeaux, France Univ Hosp Pellegrin Bordeaux France iv Hosp Pellegrin, Bordeaux, France Dalhousie Univ, Dept Med, Halifax, NS B3H 3J5, Canada Dalhousie Univ Halifax NS Canada B3H 3J5 Med, Halifax, NS B3H 3J5, Canada Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA Univ So Calif Los Angeles CA USA 90089 hav Sci, Los Angeles, CA 90089 USA Osaka Univ, Sch Med, Dept Psychiat, Osaka, Japan Osaka Univ Osaka JapanOsaka Univ, Sch Med, Dept Psychiat, Osaka, Japan Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA Univ Rochester Rochester NY USA 14642 t Psychiat, Rochester, NY 14642 USA Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA Univ RochesterRochester NY USA 14642 , Dept Med, Rochester, NY 14642 USA Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA Univ Rochester Rochester NY USA 14642 ept Neurol, Rochester, NY 14642 USA Moorgreen Hosp, Thornhill Res Unit, Southampton, Hants, England Moorgreen Hosp Southampton Hants England it, Southampton, Hants, England
Titolo Testata:
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
fascicolo: 7, volume: 16, anno: 2001,
pagine: 653 - 666
SICI:
0885-6230(200107)16:7<653:POADIT>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED CONTROLLED TRIAL; PLACEBO-CONTROLLED TRIAL; INTERNATIONAL PHARMACOECONOMIC CONFERENCE; ANTIDEMENTIA DRUG TRIAL; NURSING-HOME PLACEMENT; OUTCOME MEASURES; CLINICAL-TRIALS; RATING-SCALE; DEMENTIA; MULTICENTER;
Keywords:
Alzheimer's disease; cholinergic treatments; outcome measures; responders;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
77
Recensione:
Indirizzi per estratti:
Indirizzo: Winblad, B Huddinge Univ Hosp, Karolinska Inst, Alzheimer Res Ctr, NEUROTEC, B84, S-14186 Huddinge, Sweden Huddinge Univ Hosp B84 Huddinge Sweden S-14186 uddinge, Sweden
Citazione:
B. Winblad et al., "Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success", INT J GER P, 16(7), 2001, pp. 653-666

Abstract

The traditional aim of Alzheimer's disease treatment in clinical trials has been to improve cognitive abilities. It has become increasingly clear, however, that other aspects are important in assessing treatment responses. Agroup of 10 physicians recently gathered to review the current criteria for assessing treatment success in Alzheimer's disease. While cognition has been previously viewed as the primary measure of efficacy, areas such as functional abilities, behaviour, caregiver burden, quality of life and resource utilization all need to be comprehensively assessed to fully evaluate treatment effects in patients with Alzheimer's disease, as well as their impacts on caregivers and society. Postponing or slowing decline in any of theseareas may represent an important benefit and should be considered as an outcome measure in clinical trials, clinical practice and decisionmaking about healthcare budgets. Accepted instruments are available for assessing outcomes in each aspect of Alzheimer's disease, but they need to be selected carefully to provide valid, meaningful data. Some of the most frequently usedoutcome measures in Alzheimer's disease are reviewed. Using expanded criteria for treatment success and clinically relevant outcome measures, data from currently available studies show that cholinesterase inhibitors produce clinically meaningful long-term benefits in multiple domains in patients with Alzheimer's disease. Copyright (C) 2001 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 21:13:42